Patents Assigned to INVECTYS SAS
  • Recombinant measles vaccine expressing hTERT
    Patent number: 11351246
    Abstract: The invention relates a recombinant measles virus plasmid capable of expressing a human telomerase reverse transcriptase (hTERT) protein fused at N-terminus with a protein enhancing addressing of the hTERT protein to proteasome. The invention further relates to a vaccine comprising said plasmid or particles rescued therefrom, and uses thereof, especially in preventing or treating a tumor in a patient.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: June 7, 2022
    Assignees: INVECTYS SAS, INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Pierre Langlade Demoyen, Frédéric Tangy, Elodie Pliquet